Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 44Hodgkin Disease 8Neoplasm Metastasis 6Neoplasms 5Leiomyosarcoma 5Skin Neoplasms 4Lymphoma 4Uveal Melanoma 3Sarcoma 3Hematologic Diseases 2Solid Tumor 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Liposarcoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Neoplasms 1Advanced Melanoma 1

Interventions

binimetinib 2Watchful Waiting 2Aminolevulinic Acid 2palbociclib 1ipatasertib 1exemestane 1encorafenib 1baricitinib 1atezolizumab 1Vemurafenib 1VP-102 1Trabectedin 1Paclitaxel 1Injections, Intradermal 1Gonadotropin-Releasing Hormone 1Everolimus 1Dacarbazine 1Cantharidin 1BF-200 ALA 1Anastrozole 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Skin Diseases × Dacarbazine × Clear all
NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡